San Diego biotech fails PhII in ear-ringing and will cut costs in pipeline pruning
Last week, a hearing disorder biotech thought it was headed toward a Phase III trial in the first half of next year for its drug …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
